FDA Removes Clinical Hold From Aardvark Therapeutics' Investigational New Drug Application For ARD-101 To Treat Hyperphagia In Prader-Willi Syndrome
Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of
The FDA said Aardvark can test its hunger-stopping medicine on patients. When regulators approve testing, it means the early work looked safe enough to move forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.